Mutations of the TP53 gene in adenocarcinoma and squamous cell carcinoma of the cervix: A systematic review

Gynecologic Oncology

Volumn 128, Issue 3, 2013, Pages 442-448

  Tornesello, Maria Lina ^a   Buonaguro, Luigi ^a   Buonaguro, Franco M ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cervical adenocarcinoma; Cervical squamous cell carcinoma; Human papillomavirus; TP53 mutation

Indexed keywords

PROTEIN P21; PROTEIN P53;

ASIA; CANCER PROGNOSIS; CODON; DNA STRAND; GENE FREQUENCY; GENE MUTATION; GEOGRAPHY; HUMAN; MEDICAL RECORD REVIEW; NORTH AMERICA; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; UTERINE CERVIX ADENOCARCINOMA; UTERINE CERVIX CARCINOMA;

EID: 84873739422     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.11.017     Document Type: Article

References (48)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. A.I. Spriggs, and M.M. Boddington Progression and regression of cervical lesions. Review of smears from women followed without initial biopsy or treatment J Clin Pathol 33 1980 517 522
3. W.M. Christopherson, N. Nealon, and L.A. Gray Sr. Noninvasive precursor lesions of adenocarcinoma and mixed adenosquamous carcinoma of the cervix uteri Cancer 44 1979 975 983
4. V. Galic, T.J. Herzog, S.N. Lewin, A.I. Neugut, W.M. Burke, and Y.S. Lu Prognostic significance of adenocarcinoma histology in women with cervical cancer Gynecol Oncol 125 2012 287 291
5. V. Bouvard, R. Baan, K. Straif, Y. Grosse, B. Secretan, and G.F. El A review of human carcinogens - part B: biological agents Lancet Oncol 10 2009 321 322
6. C.A. Moody, and L.A. Laimins Human papillomavirus oncoproteins: pathways to transformation Nat Rev Cancer 10 2010 550 560
7. N. Hafner, C. Driesch, M. Gajda, L. Jansen, R. Kirchmayr, and I.B. Runnebaum Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts Oncogene 27 2008 1610 1617
8. H.H. zur Papillomaviruses and cancer: from basic studies to clinical application Nat Rev Cancer 2 2002 342 350
9. B.I. Bertelsen, S.J. Steine, R. Sandvei, A. Molven, and O.D. Laerum Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation Int J Cancer 118 2006 1877 1883
10. A. Zhang, S. Maner, R. Betz, T. Angstrom, U. Stendahl, and F. Bergman Genetic alterations in cervical carcinomas: frequent low-level amplifications of oncogenes are associated with human papillomavirus infection Int J Cancer 101 2002 427 433
11. I. Imoto, H. Tsuda, A. Hirasawa, M. Miura, M. Sakamoto, and S. Hirohashi Expression of cIAP1, a target for 11q22 amplification, correlates with resistance of cervical cancers to radiotherapy Cancer Res 62 2002 4860 4866
12. L.V. Alonio, M.A. Picconi, D. Dalbert, J. Mural, O. Bartt, and G. Bazan Ha-ras oncogene mutation associated to progression of papillomavirus induced lesions of uterine cervix J Clin Virol 27 2003 263 269
13. T.H. Cheung, K.W. Lo, S.F. Yim, L.K. Chan, M.S. Heung, and C.S. Chan Epigenetic and genetic alternation of PTEN in cervical neoplasm Gynecol Oncol 93 2004 621 627
14. S.N. Wingo, T.D. Gallardo, E.A. Akbay, M.C. Liang, C.M. Contreras, and T. Boren Somatic LKB1 mutations promote cervical cancer progression PLoS One 4 2009 e5137
15. M. Tommasino, R. Accardi, S. Caldeira, W. Dong, I. Malanchi, and A. Smet The role of TP53 in cervical carcinogenesis Hum Mutat 21 2003 307 312
16. J.M. Nigro, S.J. Baker, A.C. Preisinger, J.M. Jessup, R. Hostetter, and K. Cleary Mutations in the p53 gene occur in diverse human tumour types Nature 342 1989 705 708
17. A. Petitjean, M.I. Achatz, A.L. Borresen-Dale, P. Hainaut, and M. Olivier TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes Oncogene 26 2007 2157 2165
18. A.J. Munro, S. Lain, and D.P. Lane P53 abnormalities and outcomes in colorectal cancer: a systematic review Br J Cancer 92 2005 434 444
19. B. Vogelstein, D. Lane, and A.J. Levine Surfing the p53 network Nature 408 2000 307 310
20. K.H. Vousden Switching from life to death: the Miz-ing link between Myc and p53 Cancer Cell 2 2002 351 352
21. S.P. Hussain, and C.C. Harris Molecular epidemiology and carcinogenesis: endogenous and exogenous carcinogens Mutat Res 462 2000 311 322
22. B. Vogelstein, and K.W. Kinzler Carcinogens leave fingerprints Nature 355 1992 209 210
23. G. Giglia-Mari, and A. Sarasin TP53 mutations in human skin cancers Hum Mutat 21 2003 217 228
24. G.P. Pfeifer, M.F. Denissenko, M. Olivier, N. Tretyakova, S.S. Hecht, and P. Hainaut Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers Oncogene 21 2002 7435 7451
25. P. Hainaut, and G.P. Pfeifer Patterns of p53 G→T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke Carcinogenesis 22 2001 367 374
26. I.C. Hsu, R.A. Metcalf, T. Sun, J.A. Welsh, N.J. Wang, and C.C. Harris Mutational hotspot in the p53 gene in human hepatocellular carcinomas Nature 350 1991 427 428
27. S.P. Hussain, J. Schwank, F. Staib, X.W. Wang, and C.C. Harris TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer Oncogene 26 2007 2166 2176
28. S. Jankovic, D. Bukvic, J. Marinkovic, J. Jankovic, I. Maric, and L. Djukanovic Time trends in Balkan endemic nephropathy incidence in the most affected region in Serbia, 1977-2009: the disease has not yet disappeared Nephrol Dial Transplant 26 2011 3171 3176
29. T. Nedelko, V.M. Arlt, D.H. Phillips, and M. Hollstein TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours Int J Cancer 124 2009 987 990
30. M. Moriya, N. Slade, B. Brdar, Z. Medverec, K. Tomic, and B. Jelakovic TP53 mutational signature for aristolochic acid: an environmental carcinogen Int J Cancer 129 2011 1532 1536
31. P.A. Jones, W.M. Rideout III, J.C. Shen, C.H. Spruck, and Y.C. Tsai Methylation, mutation and cancer Bioessays 14 1992 33 36
32. M. Scheffner, K. Munger, J.C. Byrne, and P.M. Howley The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines Proc Natl Acad Sci U S A 88 1991 5523 5527
33. T. Crook, D. Wrede, J.A. Tidy, W.P. Mason, D.J. Evans, and K.H. Vousden Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours Lancet 339 1992 1070 1073
34. T. Crook, and K.H. Vousden Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens EMBO J 11 1992 3935 3940
35. H. Tsuda, and S. Hirohashi Frequent occurrence of p53 gene mutations in uterine cancers at advanced clinical stage and with aggressive histological phenotypes Jpn J Cancer Res 83 1992 1184 1191
36. T.D. Kessis, R.J. Slebos, S.M. Han, K. Shah, X.F. Bosch, and N. Munoz p53 gene mutations and MDM2 amplification are uncommon in primary carcinomas of the uterine cervix Am J Pathol 143 1993 1398 1405
37. R.M. Busby-Earle, C.M. Steel, A.R. Williams, B. Cohen, and C.C. Bird p53 mutations in cervical carcinogenesis - low frequency and lack of correlation with human papillomavirus status Br J Cancer 69 1994 732 737
38. T. Soussi, D. Hamroun, L. Hjortsberg, J.M. Rubio-Nevado, J.L. Fournier, and C. Beroud MUT-TP53 2.0: a novel versatile matrix for statistical analysis of TP53 mutations in human cancer Hum Mutat 31 2010 1020 1025
39. S. Kato, S.Y. Han, W. Liu, K. Otsuka, H. Shibata, and R. Kanamaru Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis Proc Natl Acad Sci U S A 100 2003 8424 8429
40. T. Soussi, B. Asselain, D. Hamroun, S. Kato, C. Ishioka, and M. Claustres Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodologic bias in mutation detection Clin Cancer Res 12 2006 62 69
41. K. Jiko, H. Tsuda, S. Sato, and S. Hirohashi Pathogenetic significance of p53 and c-Ki-ras gene mutations and human papillomavirus DNA integration in adenocarcinoma of the uterine cervix and uterine isthmus Int J Cancer 59 1994 601 606
42. P. Tenti, S. Pavanello, L. Padovan, A. Spinillo, N. Vesentini, and R. Zappatore Analysis and clinical implications of p53 gene mutations and human papillomavirus type 16 and 18 infection in primary adenocarcinoma of the uterine cervix Am J Pathol 152 1998 1057 1063
43. S. Andersson, A.C. Hellstrom, Z.P. Ren, and E. Wilander The carcinogenic role of oncogenic HPV and p53 gene mutation in cervical adenocarcinomas Med Oncol 23 2006 113 119
44. C. Schmutte, A.S. Yang, T.T. Nguyen, R.W. Beart, and P.A. Jones Mechanisms for the involvement of DNA methylation in colon carcinogenesis Cancer Res 56 1996 2375 2381
45. S. Ambs, W.P. Bennett, W.G. Merriam, M.O. Ogunfusika, S.M. Oser, and A.M. Harrington Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer J Natl Cancer Inst 91 1999 86 88
46. N.M. Vaninetti, L. Geldenhuys, G.A. Porter, H. Risch, P. Hainaut, and D.L. Guernsey Inducible nitric oxide synthase, nitrotyrosine and p53 mutations in the molecular pathogenesis of Barrett's esophagus and esophageal adenocarcinoma Mol Carcinog 47 2008 275 285
47. A.L. Jackson, and L.A. Loeb The contribution of endogenous sources of DNA damage to the multiple mutations in cancer Mutat Res 477 2001 7 21
48. M. Matsumoto, M. Furihata, A. Kurabayashi, K. Araki, S. Sasaguri, and Y. Ohtsuki Association between inducible nitric oxide synthase expression and p53 status in human esophageal squamous cell carcinoma Oncology 64 2003 90 96